BidaskClub cut shares of Aduro BioTech (NASDAQ:ADRO) from a strong-buy rating to a buy rating in a report issued on Friday morning.
Other equities analysts also recently issued research reports about the stock. HC Wainwright dropped their price target on shares of Aduro BioTech from $18.00 to $9.50 and set a buy rating for the company in a research note on Wednesday, December 13th. Oppenheimer set a $15.00 price target on shares of Aduro BioTech and gave the stock a buy rating in a research note on Monday, December 11th. Zacks Investment Research upgraded shares of Aduro BioTech from a hold rating to a buy rating and set a $7.50 price target for the company in a research note on Tuesday, March 6th. Cantor Fitzgerald restated a buy rating and issued a $15.00 price target on shares of Aduro BioTech in a research note on Monday, March 5th. Finally, Canaccord Genuity restated a buy rating on shares of Aduro BioTech in a research note on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $14.50.
Shares of NASDAQ:ADRO traded down $0.20 during trading on Friday, hitting $8.05. The company’s stock had a trading volume of 417,743 shares, compared to its average volume of 720,345. The company has a market cap of $668.30, a price-to-earnings ratio of -5.67 and a beta of 2.07. Aduro BioTech has a fifty-two week low of $5.82 and a fifty-two week high of $14.05.
Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.35) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.01. The business had revenue of $3.76 million during the quarter, compared to the consensus estimate of $4.32 million. Aduro BioTech had a negative net margin of 532.88% and a negative return on equity of 37.86%. research analysts expect that Aduro BioTech will post -1.29 earnings per share for the current fiscal year.
In other news, insider Stephen T. Isaacs sold 72,051 shares of Aduro BioTech stock in a transaction on Friday, March 9th. The shares were sold at an average price of $8.48, for a total transaction of $610,992.48. Following the completion of the sale, the insider now directly owns 231,380 shares of the company’s stock, valued at approximately $1,962,102.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Elsas Andrea Van sold 6,874 shares of Aduro BioTech stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.48, for a total transaction of $44,543.52. Following the sale, the insider now directly owns 216,669 shares of the company’s stock, valued at $1,404,015.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 118,925 shares of company stock valued at $1,011,936. Corporate insiders own 6.60% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC purchased a new stake in shares of Aduro BioTech during the 4th quarter worth $140,000. SG Americas Securities LLC purchased a new stake in Aduro BioTech in the third quarter valued at $167,000. Fox Run Management L.L.C. lifted its position in Aduro BioTech by 91.4% in the fourth quarter. Fox Run Management L.L.C. now owns 22,775 shares of the biotechnology company’s stock valued at $171,000 after acquiring an additional 10,875 shares during the last quarter. Trexquant Investment LP purchased a new stake in Aduro BioTech in the third quarter valued at $175,000. Finally, Nisa Investment Advisors LLC lifted its position in Aduro BioTech by 2,294.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 24,420 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 23,400 shares during the last quarter. 44.94% of the stock is owned by institutional investors and hedge funds.
WARNING: “Aduro BioTech (ADRO) Stock Rating Lowered by BidaskClub” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/aduro-biotech-adro-stock-rating-lowered-by-bidaskclub.html.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.